Abstract:Adjuvants for vaccines with characteristics of improving adaptive immunity particularly via leverage of antigen presenting cells (APCs) are currently lacking. In a previous work we obtained a new soluble 300 kDa homogeneous β-glucan named GFPBW1 from the fruit bodies of Granola frondosa . GFPBW1 could activate macrophages by targeting dendritic cell associated C-type lectin 1 (Dectin-1)/Syk/NF-κB signaling to achieve antitumour effects. In this study the adjuvant effects of GFPBW1 were explored with OVA-antigen and B16-OVA tumor model. We showed that GFPBW1 (5, 50, 500 μg/mL) dose-dependently promoted activation and maturation of APCs in vitro by increasing CD80, CD86 and MHC II expression. We immunized female mice with OVA in combination with GFPBW1 (50 or 300 μg) twice with an interval of two weeks. GFPBW1 markedly and dose-dependently increased OVA-specific antibody titers of different subtypes including IgG1, IgG2a, IgG2b and IgG3, suggesting that it could serve as an adjuvant for both Th1 and Th2 type immune responses. Furthermore, GFPBW1 in combination with aluminum significantly increased the titers of OVA-specific IgG2a and IgG2b, but not those of IgG1, suggesting that GFPBW1 could be used as a co-adjuvant of aluminum to compensate for Th1 deficiency. For mice immunized with OVA plus GFPBW1, no obvious pathological injury was observed in either major organs or injection sites, and no abnormalities were noted for any of the hematological parameters. When GFPBW1 served as an adjuvant in the B16-OVA cancer vaccine models, it could accomplish entire tumor suppression with preventive vaccines, and enhance antitumour efficacy with therapeutic vaccines. Differentially expressed genes were found to be enriched in antigen processing process, specifically increased tumor infiltration of DCs, B1 cells and plasma cells in the OVA plus GFPBW1 group, in accordance with its activation and maturation function of APCs. Collectively, this study systematically describes the properties of GFPBW1 as a novel potent and safe adjuvant and highlights its great potential in vaccine development.

A surfactin cyclopeptide of WH1fungin used as a novel adjuvant for intramuscular and subcutaneous immunization in mice.

WH1fungin a Surfactin Cyclic Lipopeptide is a Novel Oral Immunoadjuvant.

A Surfactin Lipopeptide Adjuvanted Hepatitis B Vaccines Elicit Enhanced Humoral And Cellular Immune Responses In Mice

Immunomodulation Therapy of Diabetes by Oral Administration of a Surfactin Lipopeptide in NOD Mice.

Resiquimod and Polyinosinic–polycytidylic Acid Formulation with Aluminum Hydroxide As an Adjuvant for Foot-and-mouth Disease Vaccine

The Enhance of Mice Immune Response by Porcine IFN- α on Foot and Mouth Disease Recombinant Vaccine

A Novel Emulsion Adjuvant Increases the Immunogenic Responses and Protective Efficacy of an Inactivated Influenza Vaccine in BALB/c Mice

Ginseng stem-leaf saponins (GSLS) and mineral oil act synergistically to enhance the immune responses to vaccination against foot-and-mouth disease in mice.

Increased Humoral Immune Responses of Pigs to Foot‐and‐Mouth Disease Vaccine Supplemented with Ginseng Stem and Leaf Saponins

Immunological adjuvant effect of the peptide fraction from the larvae of Musca domestica

GFPBW1, a β-glucan from Grifola frondosa as vaccine adjuvant: APCs activation and maturation

Enhanced Immune Response to Foot-and-mouth Disease Vaccine by Oral Administration of Ginseng Stem-Leaf Saponins

Polysaccharide from Atractylodes macrocephala Koidz Binding with Zinc Oxide Nanoparticles as a Novel Mucosal Immune Adjuvant for H9N2 Inactivated Vaccine

Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice

Mf59 Formulated With Cpg Odn As A Potent Adjuvant Of Recombinant Hsp65-Muc1 For Inducing Anti-Muc1(+) Tumor Immunity In Mice

[Immunopotentiation of Novel Adjuvant SWZY on the Poorly Immunogenic Murine Melanoma Vaccine].

Effect of Edible Fungal Polysaccharides on Improving Influenza Vaccine Protection in Mice

Combination of STING Pathway Agonist With Saponin Is an Effective Adjuvant in Immunosenescent Mice

Comparison of adjuvants for a spray freeze-dried whole inactivated virus influenza vaccine for pulmonary administration

Adjuvant Effects of L. acidophilus LW1 on Immune Responses to the Foot-and-Mouth Disease Virus DNA Vaccine in Mice

Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant